CION Ameerpet
Nodular sclerosing Hodgkin lymphoma is the most frequent form of classical Hodgkin lymphoma, most often affecting the neck and chest of young adults. It is highly treatable. This guide explains what it is, how it is diagnosed, and how CION's lymphoma team plans care.
Nodular sclerosis Hodgkin lymphoma is the most common subtype of classical Hodgkin lymphoma — the family of lymphomas defined by the presence of Reed-Sternberg cells. It accounts for roughly 60–70% of classical Hodgkin cases in published series. Its name comes from what a pathologist sees down the microscope: the affected lymph node is broken up into nodules by bands of fibrous, scar-like tissue — the "sclerosis".
This subtype has a strong tendency to involve the lymph nodes of the neck and the chest (the mediastinum), and it is particularly common in adolescents and young adults. Unlike some other Hodgkin subtypes, it affects men and women almost equally. The encouraging headline is that nodular sclerosing Hodgkin lymphoma is one of the most treatable of all cancers, especially when found early.
This page explains the subtype in depth — its symptoms, how it is diagnosed and staged, how it is treated, and its outlook. For the wider picture, see the Lymphoma hub and what Hodgkin lymphoma is. If you already have a diagnosis, book a free consultation with CION's lymphoma team.
Nodular sclerosis is the most common form of classical Hodgkin lymphoma, making up roughly 60–70% of cases, and it is one of the few cancers with a distinct peak in adolescents and young adults. It is also unusual among Hodgkin subtypes in affecting men and women at nearly equal rates, and it frequently shows up as a mass in the chest on imaging. (Source: subtype distribution as described in NCCN and ESMO Hodgkin lymphoma guidelines.)
Classical Hodgkin lymphoma has four subtypes, all sharing Reed-Sternberg cells but differing in appearance and behaviour. Nodular sclerosis is the most common. Nodular lymphocyte-predominant Hodgkin lymphoma is a separate disease, not a classical subtype.
| Subtype | Share of cases | Key features |
|---|---|---|
| Nodular sclerosis | ~60–70% | Fibrous bands dividing the node into nodules; often involves the chest; peaks in young adults |
| Mixed cellularity | ~20–25% | Mixed background cells; more common at older ages and with certain infections |
| Lymphocyte-rich | ~5% | Many background lymphocytes; often early-stage; generally favourable |
| Lymphocyte-depleted | <1% | Rare and aggressive; few lymphocytes on the slide |
| Nodular lymphocyte-predominant | ~5% (separate entity) | Distinct disease — "popcorn" LP cells that are CD20-positive; managed differently |
Shares are approximate and vary by individual and by series; classification follows the WHO scheme referenced by NCCN and ESMO. The exact subtype is decided by a pathologist on tissue, not by a scan alone.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just diagnosed with nodular sclerosing Hodgkin lymphoma, want to understand your stage and PET-CT, or need a second opinion before treatment? CION's lymphoma team is here.
Because this subtype favours the neck and chest, its signs often reflect those sites. The classic first sign is a painless, firm swelling of a lymph node, most often in the neck or just above the collarbone. When there is a chest (mediastinal) mass, it can press on nearby structures. Common signs include:
These signs have many ordinary causes and most are not lymphoma. But a lump that is new, firm and persistent, or B symptoms without an obvious cause, should be assessed. For a fuller guide, see Hodgkin lymphoma symptoms, or speak to a CION specialist.
Confirming this subtype — and mapping how far it has spread — follows a clear pathway. CION coordinates the biopsy and arranges the pathology, marker testing and staging scans, then reviews everything at a tumour board.
Diagnosis rests on a tissue biopsy — ideally an excision biopsy of a whole affected node, or a generous core biopsy. A pathologist looks for the tell-tale fibrous bands and nodular pattern, along with Reed-Sternberg cells. A needle aspirate alone is usually not enough to confirm the subtype.
Marker testing confirms classical Hodgkin lymphoma: the Reed-Sternberg cells typically express CD30 and CD15, and are usually negative for CD45 and CD20. These testing concepts help distinguish nodular sclerosis from nodular lymphocyte-predominant Hodgkin lymphoma, whose "popcorn" cells are CD20-positive.
Once the diagnosis is confirmed, a PET-CT scan maps every site of disease and assigns a stage from I to IV. A bone-marrow assessment and blood tests may be added. Accurate staging — and noting any bulky chest disease — directly shapes the plan. The full staging and treatment pathway is set out on Lymphoma Treatment in Hyderabad, in line with NCCN and ESMO guidance.
In classical Hodgkin lymphoma, the abnormal Reed-Sternberg cells typically carry the CD30 marker on their surface. This is not just a diagnostic clue — CD30 is a genuine treatment target, and testing for markers like CD30 and CD15 is how a pathologist confirms the nodular sclerosis subtype and separates it from other lymphomas that can look similar. (Source: immunophenotype as described in NCCN and ESMO Hodgkin lymphoma guidelines.)
Nodular sclerosing Hodgkin lymphoma is highly treatable, and the plan is tailored to the stage, the presence of bulky chest disease and your overall health. Every case is reviewed by CION's multidisciplinary tumour board before treatment begins. We describe therapy by drug class and mechanism here; the exact regimens are individualised and explained on the treatment page. The main building blocks are:
The backbone of treatment is combination chemotherapy given over several cycles. The number of cycles depends on the stage and risk. CION's medical oncology team delivers systemic therapy directly, with careful supportive care to manage side effects.
For many patients — particularly those with early-stage or bulky mediastinal disease — chemotherapy is followed by precision radiation (IMRT) to the involved sites. CION delivers IMRT directly, shaping the beam to spare the heart, lungs and breast tissue, which is especially important in the many young patients with this subtype.
Modern care uses an interim PET-CT partway through chemotherapy to see how well the lymphoma is responding. A strong early response can allow treatment to be de-escalated to reduce long-term side effects, while a slower response can prompt intensification. This response-adapted approach is central to NCCN and ESMO recommendations.
If the lymphoma relapses or does not respond fully, options include an anti-CD30 antibody-drug conjugate and immune checkpoint inhibitors, delivered directly by CION. High-dose therapy with a stem-cell transplant, and CAR-T cellular therapy where appropriate, are coordinated through accredited partner facilities rather than delivered in-house.
The outlook for nodular sclerosing Hodgkin lymphoma is very encouraging. Across large published series, overall survival for classical Hodgkin lymphoma is commonly reported around 80–90%, with early-stage disease doing better still. For context, the common aggressive non-Hodgkin lymphoma DLBCL sits around 60–70% (all figures vary by individual and by series, per NCCN and ESMO). Outcome depends chiefly on the stage, whether there is bulky mediastinal disease, and the interim PET-CT response.
Because so many people with this subtype are young, survivorship care is a core part of the plan — protecting long-term heart and lung health, discussing fertility before treatment where relevant, and arranging structured follow-up. For a fuller discussion of the numbers, see Hodgkin lymphoma survival & cure rates. We avoid promising any guaranteed result — instead we set out realistic, evidence-based expectations for your specific situation.
A Hodgkin lymphoma diagnosis carries important detail, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service, delivered by our lymphoma hospital team in Hyderabad. You deserve a plan built around healing, with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if your subtype is uncertain or you want to weigh treatment options carefully.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Nodular sclerosis Hodgkin lymphoma is the most common subtype of classical Hodgkin lymphoma, accounting for roughly 60–70% of cases. Under the microscope, the affected lymph node is divided into nodules by bands of fibrous (scar-like) tissue — this "sclerosis" is what gives the subtype its name. It also contains the characteristic Reed-Sternberg cells seen in classical Hodgkin lymphoma. Nodular sclerosing Hodgkin lymphoma most often begins in the lymph nodes of the neck and the chest (mediastinum), and it is especially common in adolescents and young adults. It is generally very treatable, and the subtype is confirmed on a tissue biopsy reviewed by a pathologist, not on a scan alone.
Nodular sclerosis is by far the most common form of classical Hodgkin lymphoma, making up about 60–70% of all classical Hodgkin cases in published series. Unlike some other subtypes, it affects men and women almost equally. It has a notable peak in adolescents and young adults aged roughly 15 to 35, which is one reason it is often diagnosed in otherwise fit, active people. It frequently presents with disease in the chest (a mediastinal mass) that may be found on a chest scan. Because it is so treatable, an accurate diagnosis and a clear, coordinated plan matter enormously — which is what CION's lymphoma team is built to provide.
The most common first sign is a painless, firm swelling of a lymph node — most often in the neck or above the collarbone. Because this subtype frequently involves the chest, some people are found to have a mass in the mediastinum on imaging, which can cause a cough, breathlessness or chest discomfort. So-called "B symptoms" may also appear: unexplained fevers, drenching night sweats, and weight loss. Some people notice itching or discomfort in swollen nodes after drinking alcohol. These signs have many ordinary causes and most are not lymphoma. For a full guide to warning signs, see Hodgkin lymphoma symptoms. Any lump that is new, firm and persists beyond a few weeks should be checked.
Diagnosis requires a tissue biopsy — ideally an excision or a generous core biopsy of an affected lymph node — reviewed by a pathologist. The pathologist looks for the fibrous bands and nodular pattern, together with Reed-Sternberg cells, and confirms the subtype with immunohistochemistry (classical Hodgkin cells typically express the CD30 marker and CD15). Staging then maps how much of the body is involved, usually with a PET-CT scan, and sometimes a bone-marrow assessment. Blood tests complete the picture. At CION, the biopsy is coordinated, the pathology and marker testing are arranged, and every case is discussed at a multidisciplinary tumour board before a plan is set. For the full pathway, see Lymphoma Treatment in Hyderabad.
Treatment depends on the stage and risk features, but nodular sclerosing Hodgkin lymphoma is among the most treatable of all cancers. Most people receive combination chemotherapy, sometimes followed by radiation therapy (IMRT) to the involved area — particularly when there is bulky disease in the chest. Modern protocols use PET-CT scans partway through treatment to check the response and adjust intensity, an approach called response-adapted therapy. CION delivers chemotherapy, antibody-based and targeted therapy, and precision radiation directly, and coordinates stem-cell transplant through accredited partner facilities if it is ever needed for relapsed disease. We describe treatment by drug class here; specific regimens are individualised and explained on the treatment page, guided by NCCN and ESMO recommendations.
The outlook for classical Hodgkin lymphoma, including the nodular sclerosis subtype, is very good. Across large published series, overall survival is commonly reported in the region of 80–90%, with early-stage disease doing even better; by comparison, the common aggressive non-Hodgkin lymphoma DLBCL sits around 60–70% (figures vary by individual and by series, per NCCN and ESMO). Outcome depends on stage, whether there is bulky mediastinal disease, and how the tumour responds on the mid-treatment PET-CT. Because so many patients are young, long-term survivorship care — protecting the heart, lungs and fertility — is a core part of the plan. See Hodgkin lymphoma survival & cure rates for a fuller discussion.
Nodular sclerosis is one of four subtypes of classical Hodgkin lymphoma, and it is defined by two features: fibrous bands dividing the node into nodules, and classical Reed-Sternberg cells that carry the CD30 and CD15 markers. It differs from the other classical subtypes (mixed cellularity, lymphocyte-rich and lymphocyte-depleted) mainly in this scarring pattern and in its tendency to affect the chest in young adults. It is entirely separate from nodular lymphocyte-predominant Hodgkin lymphoma, which is a distinct disease with different cells (LP or "popcorn" cells, CD20-positive) and is managed differently. Getting the exact subtype right on biopsy is what allows the team to tailor treatment correctly.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.